A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
An Open-Label, Randomized, 2 Way Crossover, Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Kanto, Japan
- Reserch site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with type 2 diabetes mellitus in stable condition who have normal renal function or moderate renal impairment
- Body mass index of ≥18.5 kg/m2 and ≤39.9 kg/m2 at screening
- HbA1c of ≥6.5% and ≤10.5% at screening
Exclusion Criteria:
- Type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus
- Past or current history of severe diabetic complications
- Patients requiring insulin therapy
- History of hereditary glucose-galactose malabsorption or primary renal glucosuria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TA-7284 Low
|
Low
|
|
Experimental: TA-7284 High
|
High
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of Renal Function on Maximum Plasma Concentration of TA-7284
Time Frame: For 72 hours after each administration
|
For 72 hours after each administration
|
|
|
Effect of Renal Function on Area Under the Plasma Concentration-time Curve From Zero up to Infinity of TA-7284
Time Frame: For 72 hours after each administration
|
For 72 hours after each administration
|
|
|
Effect of Renal Function on Urinary Glucose Excretion of TA-7284
Time Frame: For 24 hours after each administration
|
For 24 hours after each administration
|
|
|
Effect of Renal Function on Percent Inhibition of Renal Glucose Reabsorption (RGR) of TA-7284
Time Frame: For 24 hours after each administration
|
The percent inhibition of renal glucose reabsorption was calculated from renal glucose reabsorption (eGFR × plasma glucose AUC - urinary glucose excretion) on the preceding day and on the day of administration.
|
For 24 hours after each administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events
Time Frame: Upto approximately 14 days after last administration
|
Incidence and severity of AEs
|
Upto approximately 14 days after last administration
|
|
12-lead Electrocardiogram (ECG)
Time Frame: For 72 hours after each administration
|
Change from baseline in ECG parameters
|
For 72 hours after each administration
|
|
Vital Signs
Time Frame: For 72 hours after each administration
|
Change from baseline in Vital signs (BP, PR and BT)
|
For 72 hours after each administration
|
|
Clinical Laboratory Tests
Time Frame: For 72 hours after each administration
|
Change from baseline in Clinical laboratory tests
|
For 72 hours after each administration
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Nobuya Inagaki, MD, Kyoto University, Graduate School of Medicine
- Study Director: Kazuoki Kondo, MD, Tanabe Pharma Corporation
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Endocrine System Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Metabolic Diseases
- Glucose Metabolism Disorders
- Diabetes Mellitus
- Nutritional and Metabolic Diseases
- Diabetes Mellitus, Type 2
- Renal Insufficiency
Other Study ID Numbers
Other Study ID Numbers
- TA-7284-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.